Patient Square Capital’s Arvinas ARVN Stock Holding History

Patient Square Capital’s Portfolio ARVN Stock Details ARVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-86,627	Closed	-$1.66M	–	20
2024 Q4	$1.66M	Buy	+86,627	New	+$2.1M	0.62%	18

Other funds holding ARVN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Pfizer New York $239M AUM 232.47% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

NLVP

New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return

Patient Square Capital's ARVN Position: Q1 2025 in Review

Patient Square Capital sold out of Arvinas (ARVN) in Q1 2025, closing a stake of 86,627 shares — an estimated $1.66M sold.

Patient Square Capital first reported a position in ARVN in Q4 2024 and held it in 1 quarter. The position peaked at $1.66M in Q4 2024. 215 funds tracked by Wall St. Rank hold ARVN as of Q1 2025.

Patient Square Capital reported no remaining Arvinas position as of Q1 2025 after selling out during the quarter.
Patient Square Capital sold 86,627 Arvinas shares in Q1 2025, an estimated $1.66M.
Patient Square Capital first reported a position in Arvinas in Q4 2024 and held it in 1 quarter.
Patient Square Capital's Arvinas position peaked at $1.66M in Q4 2024.
215 funds tracked by Wall St. Rank held Arvinas as of Q1 2025.

Based on Patient Square Capital's 13F filing for Q1 2025, filed 14 May 2025.